论文部分内容阅读
目的:检测prostasin在上皮性卵巢癌患者血清及组织中的表达,探讨prostasin在上皮性卵巢癌中的临床意义。方法:运用免疫组织化学发检测组织prostasin在20例正常卵巢组织、40例卵巢上皮性良性肿瘤以及26例卵巢癌中的表达,分析其与各临床参数间的相关性,并通过ELISA法检测26例上皮性卵巢癌患者血清prostasin水平,探讨血清prostasin与组织prostasin的相关性。结果:prostasin在正常卵巢组织中无表达,在卵巢良性及恶性肿瘤中的表达率分别为24.00%和71.47%,差异具有统计学意义(x2=16.37,P<0.005);prostasin表达与病理类型、分化程度呈正相关(P=0.001,P=0.002),与临床分期无明显相关性(P=0.154);血清prostasin在卵巢上皮性癌组为14.07μg/ml,明显高于良性肿瘤组及正常对照组(P<0.001);卵巢癌组术后7天血清prostasin水平7.88μg/ml,明显低于术前(P=0.000);术前血清prostasin浓度与组织prostasin表达呈线性相关(r=0.601)。结论:prostasin对上皮性卵巢癌的发生发展、诊断及预后评估具有意义。
OBJECTIVE: To detect the expression of prostasin in the serum and tissues of patients with epithelial ovarian cancer and to explore the clinical significance of prostasin in epithelial ovarian cancer. Methods: Immunohistochemistry was used to detect the expression of prostasin in 20 cases of normal ovarian tissue, 40 cases of ovarian epithelial benign tumor and 26 cases of ovarian cancer. The correlation between the expression of prostasin and clinical parameters was analyzed by ELISA. Cases of epithelial ovarian cancer serum prostasin levels, serum prostasin and tissue prostasin correlation. Results: The expression of prostasin in normal ovarian tissue was 24.00% and 71.47% respectively, with statistical significance (x2 = 16.37, P <0.005). The expression of prostasin was correlated with pathological type, (P = 0.001, P = 0.002), but no significant correlation with clinical stage (P = 0.154). Serum prostasin was 14.07 μg / ml in ovarian epithelial carcinoma group, which was significantly higher than that in benign tumor group and normal control group (P <0.001). The level of serum prostasin in ovarian cancer group was 7.88μg / ml at 7 days after operation, which was significantly lower than that before operation (P = 0.000). The serum prostasin concentration was positively correlated with prostasin expression (r = 0.601) . Conclusion: Prostasin is of significance for the development, diagnosis and prognosis of epithelial ovarian cancer.